A syngeneic mouse glioma model for study of glioblastoma therapy

Ned E. Weiner, Richard Pyles, Claudia L. Chalk, M. Gregory Balko, Mary Ann Miller, Charissa A. Dyer, Ronald E. Warnick, Linda M. Parysek

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Animal models of human tumors serve a vital role in the development and testing of new anticancer therapies. Since the immune system is likely to play an essential role in tumor eradication, there is a particular need for modeling human disease in immunocompetent hosts. Few models of glioma have been developed in immunocompetent mice that are commercially available and none of these tumors have histological and antigenic characteristics of human gliomas. We have used a cell line, 4C8, derived from a spontaneous glioma- like tumor that arose in a transgenic mouse to develop a new glioma model. The intracranial injection of 4C8 cells into immunocompetent syngeneic B6D2F1 mice resulted in tumors that were densely cellular, developed a pseudopallisading pattern of necrosis, and expressed GFAP; all important features of human malignant gliomas. The average neurological endpoint was 51 days after intracranial injection. The 4C8 cells also grew rapidly in the flank, retaining histologic features seen in intracranial tumors. Flank tumors reached an average volume of 100 mm3, a volume ideal for therapy testing, by 34 days postinjection. These results suggest that the 4C8 mouse glioma model is an excellent system in which to test new antiglioma therapies for use in humans.

Original languageEnglish (US)
Pages (from-to)54-60
Number of pages7
JournalJournal of Neuropathology and Experimental Neurology
Volume58
Issue number1
StatePublished - Jan 1999
Externally publishedYes

Fingerprint

Glioblastoma
Glioma
Neoplasms
Therapeutics
Injections
Transgenic Mice
Immune System
Necrosis
Animal Models
Cell Line

Keywords

  • Brain tumor
  • c-neu oncogene
  • GFAP
  • Glioma, Syngeneic
  • Tumor model

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Neuroscience(all)

Cite this

Weiner, N. E., Pyles, R., Chalk, C. L., Balko, M. G., Miller, M. A., Dyer, C. A., ... Parysek, L. M. (1999). A syngeneic mouse glioma model for study of glioblastoma therapy. Journal of Neuropathology and Experimental Neurology, 58(1), 54-60.

A syngeneic mouse glioma model for study of glioblastoma therapy. / Weiner, Ned E.; Pyles, Richard; Chalk, Claudia L.; Balko, M. Gregory; Miller, Mary Ann; Dyer, Charissa A.; Warnick, Ronald E.; Parysek, Linda M.

In: Journal of Neuropathology and Experimental Neurology, Vol. 58, No. 1, 01.1999, p. 54-60.

Research output: Contribution to journalArticle

Weiner, NE, Pyles, R, Chalk, CL, Balko, MG, Miller, MA, Dyer, CA, Warnick, RE & Parysek, LM 1999, 'A syngeneic mouse glioma model for study of glioblastoma therapy', Journal of Neuropathology and Experimental Neurology, vol. 58, no. 1, pp. 54-60.
Weiner, Ned E. ; Pyles, Richard ; Chalk, Claudia L. ; Balko, M. Gregory ; Miller, Mary Ann ; Dyer, Charissa A. ; Warnick, Ronald E. ; Parysek, Linda M. / A syngeneic mouse glioma model for study of glioblastoma therapy. In: Journal of Neuropathology and Experimental Neurology. 1999 ; Vol. 58, No. 1. pp. 54-60.
@article{4c4e2707381c4e8fa95ddf70093cecd9,
title = "A syngeneic mouse glioma model for study of glioblastoma therapy",
abstract = "Animal models of human tumors serve a vital role in the development and testing of new anticancer therapies. Since the immune system is likely to play an essential role in tumor eradication, there is a particular need for modeling human disease in immunocompetent hosts. Few models of glioma have been developed in immunocompetent mice that are commercially available and none of these tumors have histological and antigenic characteristics of human gliomas. We have used a cell line, 4C8, derived from a spontaneous glioma- like tumor that arose in a transgenic mouse to develop a new glioma model. The intracranial injection of 4C8 cells into immunocompetent syngeneic B6D2F1 mice resulted in tumors that were densely cellular, developed a pseudopallisading pattern of necrosis, and expressed GFAP; all important features of human malignant gliomas. The average neurological endpoint was 51 days after intracranial injection. The 4C8 cells also grew rapidly in the flank, retaining histologic features seen in intracranial tumors. Flank tumors reached an average volume of 100 mm3, a volume ideal for therapy testing, by 34 days postinjection. These results suggest that the 4C8 mouse glioma model is an excellent system in which to test new antiglioma therapies for use in humans.",
keywords = "Brain tumor, c-neu oncogene, GFAP, Glioma, Syngeneic, Tumor model",
author = "Weiner, {Ned E.} and Richard Pyles and Chalk, {Claudia L.} and Balko, {M. Gregory} and Miller, {Mary Ann} and Dyer, {Charissa A.} and Warnick, {Ronald E.} and Parysek, {Linda M.}",
year = "1999",
month = "1",
language = "English (US)",
volume = "58",
pages = "54--60",
journal = "American Journal of Psychotherapy",
issn = "0002-9564",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - A syngeneic mouse glioma model for study of glioblastoma therapy

AU - Weiner, Ned E.

AU - Pyles, Richard

AU - Chalk, Claudia L.

AU - Balko, M. Gregory

AU - Miller, Mary Ann

AU - Dyer, Charissa A.

AU - Warnick, Ronald E.

AU - Parysek, Linda M.

PY - 1999/1

Y1 - 1999/1

N2 - Animal models of human tumors serve a vital role in the development and testing of new anticancer therapies. Since the immune system is likely to play an essential role in tumor eradication, there is a particular need for modeling human disease in immunocompetent hosts. Few models of glioma have been developed in immunocompetent mice that are commercially available and none of these tumors have histological and antigenic characteristics of human gliomas. We have used a cell line, 4C8, derived from a spontaneous glioma- like tumor that arose in a transgenic mouse to develop a new glioma model. The intracranial injection of 4C8 cells into immunocompetent syngeneic B6D2F1 mice resulted in tumors that were densely cellular, developed a pseudopallisading pattern of necrosis, and expressed GFAP; all important features of human malignant gliomas. The average neurological endpoint was 51 days after intracranial injection. The 4C8 cells also grew rapidly in the flank, retaining histologic features seen in intracranial tumors. Flank tumors reached an average volume of 100 mm3, a volume ideal for therapy testing, by 34 days postinjection. These results suggest that the 4C8 mouse glioma model is an excellent system in which to test new antiglioma therapies for use in humans.

AB - Animal models of human tumors serve a vital role in the development and testing of new anticancer therapies. Since the immune system is likely to play an essential role in tumor eradication, there is a particular need for modeling human disease in immunocompetent hosts. Few models of glioma have been developed in immunocompetent mice that are commercially available and none of these tumors have histological and antigenic characteristics of human gliomas. We have used a cell line, 4C8, derived from a spontaneous glioma- like tumor that arose in a transgenic mouse to develop a new glioma model. The intracranial injection of 4C8 cells into immunocompetent syngeneic B6D2F1 mice resulted in tumors that were densely cellular, developed a pseudopallisading pattern of necrosis, and expressed GFAP; all important features of human malignant gliomas. The average neurological endpoint was 51 days after intracranial injection. The 4C8 cells also grew rapidly in the flank, retaining histologic features seen in intracranial tumors. Flank tumors reached an average volume of 100 mm3, a volume ideal for therapy testing, by 34 days postinjection. These results suggest that the 4C8 mouse glioma model is an excellent system in which to test new antiglioma therapies for use in humans.

KW - Brain tumor

KW - c-neu oncogene

KW - GFAP

KW - Glioma, Syngeneic

KW - Tumor model

UR - http://www.scopus.com/inward/record.url?scp=0032895641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032895641&partnerID=8YFLogxK

M3 - Article

VL - 58

SP - 54

EP - 60

JO - American Journal of Psychotherapy

JF - American Journal of Psychotherapy

SN - 0002-9564

IS - 1

ER -